Edwards Lifesciences Corp on Tuesday said it stopped enrolling patients in a small study of its less-invasive mitral heart valve device due to the formation of blood clots associated with the procedure.
The company, which introduced a catheter-based approach to replacing diseased aortic heart valves in the U.S. market in 2011, is working to adapt the technique for the mitral valve.
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff14
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle15
13:37 GoPro to cut about 15 percent of workforce13
09:43 Eurogroup should be 'realistic' on Greece fiscal targets: Dijsselbloem16